India releases biosimilar manufacturing guide; Frazier wraps up packaging deal;

> India used the BIO 2012 conference to release new "similar biologics" guidelines that will require manufacturers of biosimilars prove similarity within four years of post-market safety data to either a drug licensed in India or one approved elsewhere. Story

> Catalent Pharma Solutions is partnering with formulation specialists Bend Research to offer integrated solutions for the development and manufacture of specialized multiparticulate oral controlled-release products. News

> Pluristem Therapeutics, a developer of placenta-based stem-cell therapies, is building a manufacturing facility near its headquarters in Haifa, Israel, even before it has gotten its therapy approved. Story

> Food Standards Australia New Zealand is alerting the public against taking sports food supplements containing 1,3-dimethylamylamine (DMAA) because of its links to high blood pressure and other adverse health effects. Item

> Frazier Healthcare has completed its acquisition of Catalent Pharma Solutions' U.S. commercial pharmaceutical packaging operations and will run as Packaging Coordinators, Inc., which is what it was previously named. Report

> Healthpoint Biotherapeutics says it will invest about $60 million to add 25,000 square feet of manufacturing infrastructure, as well as lab and clean room space in Fort Worth, TX, for production of its cell-based products. Announcement

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.